PMID: 7514043Feb 1, 1994Paper

Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
M G MazzucconiF Mandelli

Abstract

Thrombotic events have been reported in acute lymphoblastic leukaemia patients, especially during or after L-asparaginase administration. A so-called L-asparaginase associated coagulopathy has been well recognized, being characterized by a hypercoagulable state (decrease of antithrombin III, plasminogen, protein C, protein S and increase of prothrombin fragment F1 + 2, thrombin-antithrombin complexes and fibrinopeptide A). The aim of this study was to determine whether the supplementation of antithrombin III (AT-III) concentrates could improve the L-asparaginase associated coagulopathy, thereby blocking the activation of the haemostatic system. In 25 adult patients with acute lymphoblastic leukaemia (M 19, F6, mean age 34 years) antithrombin III (AT-III) concentrates were administered at daily doses of 50 U/kg for 10 consecutive days from the beginning of L-asparaginase therapy (6,000 U/m2/day s.c. for 7 days), given according to the GIMEMA ALL 0288 trial. A marked increase of antithrombin III was recorded on days IV-VIII-XI (P < 0.001). No changes in protein C, protein S, plasminogen, alpha 2-antiplasmin, factor VII and platelet count were observed and there was no increase in markers of hypercoagulability. There was no eviden...Continue Reading

Citations

Jun 18, 2009·Medizinische Klinik·Norbert Maurin
Oct 24, 2014·Thrombosis and Haemostasis·V De StefanoE Rossi
Aug 15, 2015·Future Oncology·Gaurav Goyal, Vijaya Raj Bhatt
Dec 31, 1997·Journal of Cardiothoracic and Vascular Anesthesia·J Petäjä, K Peltola
Apr 1, 1996·Hematology/oncology Clinics of North America·K B Green, R L Silverstein
Feb 1, 2018·British Journal of Haematology·Keith R SibsonUNKNOWN British Society for Haematology
Jan 1, 1995·European Journal of Haematology·K E SletnesF Wisløff
Nov 1, 1995·European Journal of Haematology·H CarlssonJ Kutti
Jan 1, 1996·European Journal of Haematology·U Nowak-GöttlH Jürgens
Nov 21, 2002·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·J RoemischC J Wiedermann
Oct 11, 2020·The Cochrane Database of Systematic Reviews·Cecilie U RankKjeld Schmiegelow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.